Back to top

Analyst Blog

Roche (RHHBY - Analyst Report) announced that it has entered into a definitive agreement to acquire privately-held biotechnology company, Seragon Pharmaceuticals, Inc.

The acquisition will provide Roche rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer.

As per the terms of the agreement, Roche, through its subsidiary Genentech, will make an upfront cash payment of $725 million. The agreement also includes milestone payments of up to $1 billion.

The transaction, subject to customary conditions, is expected to close in the third quarter of 2014.

Once the transaction is completed, Seragon’s portfolio will be integrated into Genentech Research and Early Development.

We note that Seragon’s lead candidate, ARN-810, is a next-generation SERD that is currently in phase I. The trial is being conducted among patients who have hormone receptor-positive breast cancer and have failed current hormonal agents.

We remind investors that Roche is a leader in drugs for oncology, immunology and infectious diseases.

In particular, Roche is a leader in breast cancer market with its HER2 franchise with strong demand for drugs like Herceptin. The HER2 franchise includes Herceptin, Perjeta and Kadcyla.

The acquisition will further strengthen Roche’s pipeline. Seragon’s pipeline of next-generation SERDs will complement Roche’s existing research and development programs in breast cancer.

Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader healthcare sector include Regeneron Pharmaceuticals (REGN - Analyst Report), Shire (SHPG - Analyst Report) and Allergan (AGN - Analyst Report). 

While Regeneron Pharma carries a Zacks Rank #1 (Strong Buy), Shire and Allergan hold a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%